Virtual Collection of Articles for 2015 World Hepatitis Day
Viral hepatitis is a serious but largely under-recognised major public health problem worldwide. It affects hundreds of millions of people globally, causing liver disease, and killing 1.4 million people every year, almost 4000 deaths a day.
Viral hepatitis is a group of infectious diseases caused by five distinct viruses - hepatitis A, B, C, D, and E. It is the most common cause of liver inflammation resulting in acute and chronic liver disease. Chronic hepatitis B or hepatitis C infections can result in liver cirrhosis and a type of liver cancer, hepatocellular carcinoma. 80% of liver cancer deaths are attributed to hepatitis B or hepatitis C. These infections can be prevented, but most people don't know how.
In the news story ‘Are we close to curing hepatitis C?’ a hepatitis C expert Giuseppe Ippolitto, Scientific Director of the National Institute for Infectious Diseases "Lazzaro Spallanzani" in Rome writes about what’s being done to tackle the disease.
On World Hepatitis Day, 28 July 2015, WHO and partners will urge policy-makers, health workers and the public to act now to prevent infection and death from hepatitis.
For more information about World Hepatitis Day, you can visit www.who.int or www.worldhepatitisalliance.org.
This Virtual collectionof articles is specially collated to support the effort to raise awareness about viral hepatitis, and to call for access to treatment, better prevention programs and government action.
Read some of the latest hepatitis research published in 2015 for free until 30 November 2015.
Read the latest research for free
International Journal of Antimicrobial Agents
Is hepatitis C virus eradication around the corner only 25 years after its discovery?
Ippolito G., Capobianchi M.R., Lanini S., Antonelli G.
International Journal of Antimicrobial Agents, volume 45, issue 2, Pages 111-112
Clinical Microbiology and Infection
Current knowledge and future perspectives on acute hepatitis C infection
Hullegie, S.J., Arends, J.E., Rijnders, B.J.A., Irving, W.L., Salmon, D., Prins, M., Wensing, A.M., Klenerman, P., Leblebicioglu, H., Boesecke, C., Rockstroh, J.K., Hoepelman, A.I.M.
Clinical Microbiology and Infection, Available online 16 April 2015
Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort
Postorino, M.C., Prosperi, M., Quiros-Roldan, E., Maggiolo, F., et.al
Clinical Microbiology and Infection, Volume 21, Issue 4, April 2015, Pages 386.e1–386.e9
Journal of Infection
Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infectionEric Lawitz, Greg Sullivan, Maribel Rodriguez-Torres, Michael Bennett, Fred Poordad, Mudra Kapoor, Prajakta Badri, Andrew Campbell, Lino Rodrigues Jr., Yiran Hu, Tami Pilot-Matias, Regis A. Vilchez
Journal of Infection, Volume 70, Issue 2, February 2015, Pages 197–205
Differences in serum microRNA profiles in hepatitis B and C virus infection
Sakura Akamatsu, C. Nelson Hayes, Masataka Tsuge, Daiki Miki, Rie Akiyama, Hiromi Abe, Hidenori Ochi, Nobuhiko Hiraga, Michio Imamura, Shoichi Takahashi, Hiroshi Aikata, Tomokazu Kawaoka, Yoshiiku Kawakami, Waka Ohishi, Kazuaki Chayama
Journal of Infection, Volume 70, Issue 3, March 2015, Pages 273–287
International Journal of Infectious Diseases
Absolute quantification of serum microRNA-122 and its correlation with liver inflammation grade and serum alanine aminotransferase in chronic hepatitis C
Wang J.-H., Jiang D., Rao H.-Y., Zhao J.-M., Wang Y., Wei L.
International Journal of Infectious Diseases, Volume 30, January 2015, Pages 52-56
An albumin, collagen IV, and longitudinal diameter of spleen scoring system superior to APRI for assessing liver fibrosis in chronic hepatitis B patients
Huang Z.-L., Chen X.-P., Zhao Q.-Y., Zheng Y.-B., Peng L., Gao Z.-L., Zhao Z.-X.
International Journal of Infectious Diseases, Volume 31, February 2015, Pages 18-22
Diagnostic Microbiology and Infectious Disease
Can serum level of HBsAg differentiate HBeAg-negative chronic hepatitis B from inactive carrier state?
Shahnaz Sali, Heidar Sharafi, Seyede Hoda Alavian, Seyed Moayed Alavian, Faranak Etesam, Shima Salimi, Muayad A. Merza, Maryam Keshvari
Diagnostic Microbiology and Infectious Disease, Volume 82, Issue 2, June 2015, Pages 114-119
Up-regulation of interleukin-22 mediates liver fibrosis via activating hepatic stellate cells in patients with hepatitis C
Li-Yuan Wu, Shuhong Liu, Yuan Liu, Chaonan Guo, Hanwei Li, Wenshu Li, Xueyuan Jin, Keming Zhang, Ping Zhao, Lai Wei, Jingmin Zhao
Clinical Immunology, Volume 158, Issue 1, May 2015, Pages 77–87
Contribution of genes for killer cell immunoglobulin-like receptors (KIR) to the susceptibility to chronic hepatitis C virus infection and to viremia
Piotr Kuśnierczyk, Iwona Mozer-Lisewska, Katarzyna Zwolińska, Arleta Elżbieta Kowala-Piaskowska, Maciej Bura, Iwona Bereszyńska, Anna Pauli, Jan Żeromski
Human Immunology, Volume 76, Issues 2–3, March 2015, Pages 102–108
Mesenchymal stem cells ameliorate experimental autoimmune hepatitis by activation of the programmed death 1 pathway
Yi Chen, Si Chen, Li-Yuan Liua, Zhuo-Lin Zoua, Yi-Jing Caia, Jin-Guo Wang, Bi Chen,
Lan-Man Xu, Zhuo Lin, Xiao-Dong Wang, Yong-Ping Chen
Immunology Letters, Volume 162, Issue 2, Part B, December 2014, Pages 222–228
Journal of Hepatology
Facts and fictions of HCV and comorbidities: Steatosis, diabetes mellitus, and cardiovascular diseases
Journal of Hepatology, Volume 61, Issue 1, Supplement, November 2014, Pages S69–S78